ARROWHEAD'S 2nd Annual Cancer Immunotherapy Conference will provide a comprehensive review of cutting edge research and development in two areas:

• Cancer Stem Cells as a new category of Targets for Immune Intervention for solid and hematological malignancies

• Hematopoietic Stem Cell and T Cell Engineering for cancer immunotherapy

The conference is bringing together leading scientists and C-Level executives from across the globe to present research, case studies and viewpoints on topics related to stem cells and cancer immunotherapy.

Conference Tracks

There will be two sequential tracks focused on the following topics:

• Tumor initiating and cancer stem cells in solid tumors: novel targets and their immunotherapeutic potential
• Novel approaches to re-direct the immune system against cancer, by engineering hematological stem cells and memory T cells

Speakers to Date Include

Adrian Bot, MD, Ph.D., Chief Scientific Officer, Kite Pharma Inc.

Maurizio Chiriva-Internati, DBSc, Ph.D., Director of Basic/Translational Research Program, Division of Hematology & Oncology, Southwest Cancer Research & Treatment Center at University Medical Center, Texas Tech University of Health Sciences Center School of Medicine

Andrew Cornforth, Ph.D., Cancer Stem Cell Program Manager, California Stem Cell, Inc.

Brian J. Czerniecki, MD, Ph.D, Rhodes-Harrington Professor in Surgical Oncology, University of Pennsylvania and Co-Director, Rena Rowan Breast Center

Soldano Ferrone, MD, Ph.D., Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School

Kenneth Geles, Ph.D., Senior Principal Scientist, Oncology Research Unit, Pfizer Inc.

Philip D. Greenberg, MD, Professor of Medicine and Immunology, University of Washington, Head, Program in Immunology, Fred Hutchinson Cancer Research Center

Elaine Hurt, Ph.D., Scientist II, MedImmune

Richard C. Koya, MD, Ph.D., Assistant Professor, Department of Surgery, Surgical Oncology, Member, JCCC Tumor Immunology Program, University of California, Los Angeles

Masoud H. Manjili, DVM, Ph.D., Associate Professor, Department of Microbiology & Immunology, Virginia Commonwealth University School of Medicine

William Matsui, MD, Associate Professor of Oncology, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

Richard A. Morgan, Ph.D., Staff Scientist, Surgery Branch, Tumor Immunology Section, National Cancer Institute

Claudia M. Palena, Ph.D., Head, Immunoregulation Group, Laboratory of Tumor Immunology and Biology, Investigator, National Cancer Institute

Daniel J Powell Jr., Ph.D, Research Assistant Professor, Department of Pathology and Laboratory Medicine and Department of Obstetrics and Gynecology, University of Pennsylvania

Robert Preti, Ph.D., President and Chief Scientific Officer, PCT Cell Therapy Services

Nicholas P. Restifo, MD, Principal Investigator, Center for Cancer Research, National Cancer Institute

David M. Spencer, Ph.D., Chief Scientific Officer, Bellicum Pharmaceuticals, Inc.

Raul Vizcardo, Ph.D., Research Scientist, RIKEN Research Center for Allergy and Immunology

Albert J. Wong, MD, Professor, Director, Brain Tumor Research Laboratories, Deptartment of Neurosurgery/Cancer Biology Program, Stanford University Medical Center

Lili Yang, Ph.D., Assistant Professor, Department of Microbiology, Immunology & Molecular Genetics, Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles

John Yu, MD, CEO, Immunocellular Therapeutics

Questions Answered

Presenters and participants will answer the following questions:

• The hierarchical versus stochastic model and the existence of cancer stem cells across various cancers: why does the controversy persist?
• What have been some of the most promising advances regarding definition of targets associated with cancer stem cells or tumor initiating cells in general?
• Why tumor initiating cells are potentially amenable to immune intervention? Have there been exciting advances in this area?
• How can targeting of cancer stem cells be more effectively achieved using a variety of immunotherapeutic platforms, such as antibodies, vaccines or immune effector cells?
• How could one leverage the normal stem cells (pluripotent and committed) of the hematopoietic and lymphoid system to re-engineer an immune repertoire against cancer?